PS
CRSP icon

Principal Securities’s CRISPR Therapeutics CRSP Stock Holding History

Principal Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-241
Closed -$15.6K – 1783
2025
Q3 		$15.6K Buy
241
+182
+308% +$10.4K ﹤0.01% 2527
2025
Q2 		$2.87K Sell
59
-12
-17% -$464 ﹤0.01% 3032
2025
Q1 		$2.79K Hold
71
– – ﹤0.01% 2948
2024
Q4 		$2.79K Sell
71
-576
-89% -$27.2K ﹤0.01% 2943
2024
Q3 		$30.4K Buy
647
+7
+1% +$355 ﹤0.01% 1916
2024
Q2 		$34.6K Sell
640
-706
-52% -$40.8K ﹤0.01% 1793
2024
Q1 		$91.7K Buy
1,346
+695
+107% +$49.8K ﹤0.01% 1309
2023
Q4 		$40.8K Buy
+651
New +$36K ﹤0.01% 1579

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
GP
GSK plc London $602M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principal Securities's CRSP Position: Q4 2025 in Review

Principal Securities sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 241 shares — an estimated $15.6K sold.

Principal Securities first reported a position in CRSP in Q4 2023 and held it in 8 quarters. The position peaked at $91.7K in Q1 2024. 480 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Principal Securities reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 241 CRISPR Therapeutics shares in Q4 2025, an estimated $15.6K.
  • Principal Securities first reported a position in CRISPR Therapeutics in Q4 2023 and held it in 8 quarters.
  • Principal Securities's CRISPR Therapeutics position peaked at $91.7K in Q1 2024.
  • 480 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.